Kineret adds RA structural damage indication
Executive Summary
Amgen Kineret (anakinra) indication expanded to include slowing the progression of structural damage in moderately to severely active rheumatoid arthritis following FDA approval Aug. 22. The intravenous drug was originally approved in 2001 for the signs and symptoms of RA...
You may also be interested in...
Kineret (correction)
Kineret (anakinra) was approved for slowing the progression of structural damage in rheumatoid arthritis Aug. 22, not Aug. 25 (1"The Pink Sheet" Sept 1, 2003, In Brief)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.